PTC Therapeutics, Inc. Variable Lease, Cost
PTC Therapeutics, Inc. (PTCT) reported Variable Lease, Cost of $5.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-19
- PTC Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $1.21M, a 16.47% increase year-over-year.
- PTC Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $1.08M, a 31.50% decline year-over-year.
- PTC Therapeutics, Inc. variable lease, cost for the quarter ending 2025-06-30 was $1.56M, a 60.74% increase year-over-year.
- PTC Therapeutics, Inc. variable lease, cost for the quarter ending 2025-03-31 was $1.34M, a 25.44% increase year-over-year.
- PTC Therapeutics, Inc. variable lease, cost for fiscal 2025 was $5.20M, a 11.50% increase from fiscal 2024.
- PTC Therapeutics, Inc. variable lease, cost for fiscal 2024 was $4.66M, a 20.27% decline from fiscal 2023.
- PTC Therapeutics, Inc. variable lease, cost for fiscal 2023 was $5.85M, a 28.29% increase from fiscal 2022.
- PTC Therapeutics, Inc. variable lease, cost for fiscal 2022 was $4.56M, a 4.49% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.29M derived: sum of 2 quarters · filed 2026-02-19 | $3.86M derived: sum of 3 quarters · filed 2026-02-19 | $5.20M 10-K · filed 2026-02-19 | |
| 2025-09-30 | $1.08M 10-Q · filed 2025-11-04 | $2.65M derived: sum of 2 quarters · filed 2025-11-04 | $3.99M 10-Q · filed 2025-11-04 | $5.03M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2025-06-30 | $1.56M 10-Q · filed 2025-08-07 | $2.90M 10-Q · filed 2025-08-07 | $3.94M derived: sum of 3 quarters · filed 2026-02-19 | $5.52M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2025-03-31 | $1.34M 10-Q · filed 2025-05-06 | $2.38M derived: sum of 2 quarters · filed 2026-02-19 | $3.96M derived: sum of 3 quarters · filed 2026-02-19 | $4.93M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.62M derived: sum of 2 quarters · filed 2026-02-19 | $3.59M derived: sum of 3 quarters · filed 2026-02-19 | $4.66M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $1.58M 10-Q · filed 2025-11-04 | $2.55M derived: sum of 2 quarters · filed 2025-11-04 | $3.62M 10-Q · filed 2025-11-04 | $5.33M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-06-30 | $973.00K 10-Q · filed 2025-08-07 | $2.04M 10-Q · filed 2025-08-07 | $3.75M derived: sum of 3 quarters · filed 2026-02-19 | $5.12M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-03-31 | $1.07M 10-Q · filed 2025-05-06 | $2.77M derived: sum of 2 quarters · filed 2026-02-19 | $4.15M derived: sum of 3 quarters · filed 2026-02-19 | $5.56M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2023-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.08M derived: sum of 2 quarters · filed 2026-02-19 | $4.49M derived: sum of 3 quarters · filed 2026-02-19 | $5.85M 10-K · filed 2026-02-19 | |
| 2023-09-30 | $1.38M 10-Q · filed 2024-11-07 | $2.79M derived: sum of 2 quarters · filed 2024-11-07 | $4.14M 10-Q · filed 2024-11-07 | $5.54M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $1.41M 10-Q · filed 2024-08-08 | $2.76M 10-Q · filed 2024-08-08 | $4.17M derived: sum of 3 quarters · filed 2025-02-27 | $5.32M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $1.35M 10-Q · filed 2024-04-25 | $2.76M derived: sum of 2 quarters · filed 2025-02-27 | $3.91M derived: sum of 3 quarters · filed 2025-02-27 | $4.83M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.56M derived: sum of 2 quarters · filed 2025-02-27 | $3.48M derived: sum of 3 quarters · filed 2025-02-27 | $4.56M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $1.15M 10-Q · filed 2023-10-26 | $2.07M derived: sum of 2 quarters · filed 2023-10-26 | $3.15M 10-Q · filed 2023-10-26 | $4.28M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $923.00K 10-Q · filed 2023-08-03 | $2.00M 10-Q · filed 2023-08-03 | $3.13M derived: sum of 3 quarters · filed 2024-02-29 | $4.27M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $1.08M 10-Q · filed 2023-04-27 | $2.20M derived: sum of 2 quarters · filed 2024-02-29 | $3.35M derived: sum of 3 quarters · filed 2024-02-29 | $4.34M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.27M derived: sum of 2 quarters · filed 2024-02-29 | $3.27M derived: sum of 3 quarters · filed 2024-02-29 | $4.36M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $1.15M 10-Q · filed 2022-10-27 | $2.14M derived: sum of 2 quarters · filed 2022-10-27 | $3.23M 10-Q · filed 2022-10-27 | $2.45B derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | $993.00K 10-Q · filed 2022-08-04 | $2.09M 10-Q · filed 2022-08-04 | $2.45B derived: sum of 3 quarters · filed 2023-02-21 | $2.45B derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-03-31 | $1.09M 10-Q · filed 2022-05-03 | $2.45B derived: sum of 2 quarters · filed 2023-02-21 | $2.45B derived: sum of 3 quarters · filed 2023-02-21 | $2.45B derived: sum of 4 quarters · filed 2023-02-21 | |
| 2020-12-31 | $2.45B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $2.45B derived: sum of 2 quarters · filed 2023-02-21 | $2.45B derived: sum of 3 quarters · filed 2023-02-21 | $2.45B 10-K · filed 2023-02-21 | $2.45M 10-K · filed 2021-02-25 |
| 2020-09-30 | $890.00K 10-Q · filed 2021-10-28 | $1.40M derived: sum of 2 quarters · filed 2021-10-28 | $1.91M 10-Q · filed 2021-10-28 | $695.14M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-06-30 | $507.00K 10-Q · filed 2021-07-29 | $734.00K 10-Q · filed 2021-07-29 | $694.25M derived: sum of 3 quarters · filed 2022-02-22 | $694.43M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-03-31 | $228.00K 10-Q · filed 2021-05-04 | $693.74M derived: sum of 2 quarters · filed 2022-02-22 | $693.92M derived: sum of 3 quarters · filed 2022-02-22 | $694.09M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2019-12-31 | $693.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $693.70M derived: sum of 2 quarters · filed 2022-02-22 | $693.86M derived: sum of 3 quarters · filed 2022-02-22 | $694.00M 10-K · filed 2022-02-22 | $694.00K 10-K · filed 2020-03-02 |
| 2019-09-30 | $184.00K 10-Q · filed 2020-10-29 | $345.00K derived: sum of 2 quarters · filed 2020-10-29 | $488.00K 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $161.00K 10-Q · filed 2020-08-05 | $304.00K 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $143.00K 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |